Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 18/20 | 0.71 |
| ▸ | DRD3 | P35462 | 18/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14715656 | 0.87 | DRD2 (0.53) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL4991586 | 0.86 | DRD2 (0.64) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL3075424 | 0.84 | DRD2 (0.55) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL14715658 | 0.84 | DRD2 (0.55) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL3080679 | 0.84 | DRD2 (0.64) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL14715653 | 0.83 | DRD2 (0.55) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL3082997 | 0.83 | DRD2 (0.60) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL3083298 | 0.83 | DRD2 (0.66) | DRD2DRD3HTR1AHTR2AHTR7 | |
| SCHEMBL14715659 | 0.81 | DRD3 (0.72) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL3079766 | 0.81 | DRD3 (0.72) | DRD2DRD3HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | claimed |
| EP-2079693-B1 | ETHER DERIVATIVES DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-7795437-B2 | Ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080103174-A1 | ETHER DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103174-A1 | ETHER DERIVATIVES | GABRE, BDNF, ADH1A | DRD2 59/4885DRD3 71/4885HTR1A 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.